Paediatric non-alcoholic fatty liver disease: an overview

被引:35
|
作者
AlKhater, S. A. [1 ]
机构
[1] Dammam Univ, Dept Pediat, Dammam, Saudi Arabia
关键词
Non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; obesity; paediatric; ELEVATED ALANINE AMINOTRANSFERASE; PLACEBO-CONTROLLED TRIAL; LIFE-STYLE INTERVENTION; VITAMIN-E TREATMENT; INSULIN-RESISTANCE; METABOLIC SYNDROME; HEPATIC STEATOSIS; URSODEOXYCHOLIC ACID; CARDIOVASCULAR RISK; OBESE CHILDREN;
D O I
10.1111/obr.12271
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a progressive disease that encompasses a spectrum of liver diseases, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Data related to survival in children are scarce, but these data firmly associate NAFLD with higher risks of hepatic and non-hepatic morbidities and mortalities compared with the general population. More recently, the association between NAFLD and cardiovascular disease among children has increasingly been recognized. Given that obesity is a major risk factor for the disease, paediatric NAFLD is becoming a global issue, paralleling the dramatic rise in obesity worldwide. NASH, which is more common in obese children, has the potential to advance to liver fibrosis and failure. It is unclear why certain patients undergo such transformation but this susceptibility is likely related to an interaction between a genetically susceptible host and the surrounding environment. Currently, treatment is largely conservative and includes lifestyle modification, attainable through healthy weight reduction via diet and exercise. In this review, current knowledge about NAFLD in children is summarized. This review aims to increase the awareness of the medical community about a hidden public health issue and to identify current gaps in the literature while providing directions for future research.
引用
收藏
页码:393 / 405
页数:13
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [22] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [23] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [24] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [25] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [26] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [27] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [28] Overview of the Association Between Non-Alcoholic Fatty Liver Disease and Hypertension
    Kakouri, Niki S.
    Thomopoulos, Costas G.
    Siafi, Eirini P.
    Valatsou, Angeliki E.
    Dimitriadis, Kyriakos S.
    Mani, Iliana P.
    Patsilinakos, Sotirios P.
    Tousoulis, Dimitrios M.
    Tsioufis, Konstantinos P.
    CARDIOLOGY DISCOVERY, 2024, 4 (01): : 30 - 37
  • [29] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [30] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512